Funded Biotechnology Startups in Los Angeles
Disclosed round sizes in Los Angeles biotechnology skew heavily toward a small number of large financings: Immix Biopharma’s $100M round (2025-12-07) is th…
Disclosed round sizes in Los Angeles biotechnology skew heavily toward a small number of large financings: Immix Biopharma’s $100M round (2025-12-07) is the only disclosed entry above $75M, while the next-largest disclosed rounds cluster at $80M (Octant Bio, 2022-04-21), $75M (Kairos Pharma, 2026-01-12), and $60M+ is otherwise limited to Capricor Therapeutics at $150M (2025-12-05) as the clear top disclosed amount across the page. Temporal clustering is noticeable despite the list being sorted by recency: 2025 contains most of the top-end rounds, including multiple late-2025 financings between 2025-12-03 and 2025-12-16 (PopID on 2025-12-03 is undisclosed; Ember LifeSciences is $17M on 2025-12-16; and Evergreen is $6M on 2026-02-04). Stage labels also show a mix of specificity and gaps: out of 29 rows, 13 are marked “Series Unknown”/blank “Series” plus 2 “undisclosed” amounts (PopID 2025-12-03 and 9 Dots 2024-07-25). The date span runs from 2020-09-23 (Force Impact Technologies Inc., $100K) to 2026-02-04 (Evergreen, $6M).
Most recent rounds
29 shownRelated listings
Frequently asked
What’s the largest disclosed biotechnology round in this Los Angeles list, and how far above the rest is it?
Capricor Therapeutics’ $150M round on 2025-12-05 is the largest disclosed amount on the page. The next-largest disclosed rounds include Immix Biopharma’s $100M (2025-12-07) and Kairos Pharma’s $75M (2026-01-12), indicating a steep drop from the top tier to the rest.
Are there notable late-2025 clusters where multiple financings appear close together?
Yes. Between 2025-12-03 and 2025-12-16, several entries land within two weeks: PopID (2025-12-03, undisclosed), Capricor Therapeutics (2025-12-05, $150M), Immix Biopharma (2025-12-07, $100M), and Ember LifeSciences (2025-12-16, $17M).
Which entries fall within the most recent ~90 days shown (late 2025 into early 2026)?
The most recent dates on the page start at 2026-02-04 (Evergreen, $6M) and run back to mid-November 2025, including Kairos Pharma (2026-01-12, $75M), Ember LifeSciences (2025-12-16, $17M), and NeuroSigma (2025-12-15, $1M). This window also includes Immix Biopharma (2025-12-07, $100M) and Capricor Therapeutics (2025-12-05, $150M).
How dominant is “Series Unknown” or missing stage information versus named stages here?
Stage specificity is limited: 13 of 29 rows are labeled “Series Unknown”/blank “Series,” and 2 additional rounds show “undisclosed” amounts (PopID on 2025-12-03 and 9 Dots on 2024-07-25). Named stages present include Series A (Evergreen 2026-02-04, Ember LifeSciences 2025-12-16, Bionaut Labs 2021-03-03), Series B (Nammi Therapeutics 2024-08-06, Octant Bio 2022-04-21), and Series C (ACELYRIN 2022-09-13).
Is the list anchored by any extreme small-round outliers on the low end?
The smallest disclosed amount is Force Impact Technologies Inc. at $100K on 2020-09-23, which sits far below the next-small disclosed amounts such as Azora Therapeutics at $580K (2023-08-08) and NeuroSigma at $1M (2025-12-15).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.